Octane

What Octane does

Octane Medical Group is a privately held Canadian medical technology company headquartered in Kingston, Ontario, founded in 2007 (with research roots dating to 1988) by Timothy Smith and Ian Grant. The company develops advanced bioprocesses, biomaterials and bioreactors for regenerative medicine, organized as a parent entity with multiple venture subsidiaries: Octane Biotech (Cocoon Platform), Octane Biotherapeutics (Novocart cartilage repair implants), Octane CDMO, Octane Clinical Systems (RUBY-FILL infusion lines for PET imaging), Octane Exo (HyperPEEK spinal implants), Octane Innovation (AI-driven bioelectric stimulation research), and Octane Orthobiologics. Its flagship technology is the Cocoon Platform, a closed-system automated bioreactor that integrates cell source isolation, expansion, washing and final product formation in a single-use disposable cassette for personalized cell therapy manufacturing. Other proprietary technologies include Skelite (silicon-stabilized calcium phosphate bioceramic), HyperPEEK biocomposite, Novocart 3D and Novocart Inject (matrix-associated autologous chondrocyte implants), and AUTOGRAFTA (living graft technology).

The company monetizes through a portfolio of revenue streams: CDMO services for ATMP developers (Octane CDMO), sales of living tissue cartilage implants (Novocart, marketed in Germany and Switzerland), spinal implant hardware (Octane Exo), and contract manufacturing of medical instrumentation including Jubilant Life Sciences' RUBY-FILL PET infusion lines. Commercialization is conducted through strategic global partners - historically Lonza for Cocoon applications (returning to Octane ownership in Q1 2026), B. Braun legacy for orthobiologics, Jubilant for nuclear medicine, and BioOra for CAR-T cell therapy in New Zealand and beyond. Octane operates 120,000+ square feet of GMP-certified facilities across Canada, Germany, and the United States, holds ISO 13485, ISO 9001, and GMP certifications, and is governed by FDA, Health Canada, and EMA quality frameworks. Its target customers include cell therapy developers, orthopedic and spinal care providers, ATMP developers seeking CDMO support, and nuclear medicine companies.

Name

Octane

Legal name

Octane Medical Group Inc.

Website

https://octaneco.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

Octane Medical Group is a privately held Canadian medical technology company that develops automated cell therapy bioreactors (Cocoon Platform), regenerative biomaterials (Skelite, HyperPEEK, Novocart), and contract manufacturing services for ATMP developers across Canada, Germany, and the United States.

Ownership category

akta.pro rank

Headquarters

HQ city

Kingston

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Contract Development and Manufacturing Organization (CDMO) Services: Octane CDMO offers contract development and manufacturing services for ATMP (Advanced Therapy Medicinal Products) developers. Services include technology transfer, fully automated cell manufacturing, medical device development, and regulatory affairs. The company has over 11,150 square metres of facilities in Canada, Germany and the United States.
2. Living Tissue Implants (NOVOCART): Sale of autologous chondrocyte implantation products (NOVOCART 3D and NOVOCART Inject) for cartilage repair. Products are living tissue implants made from patient's own cells. Prior to acquisition, approximately 30,000+ implants were manufactured for patients in Germany and Switzerland.
3. Spinal Implants (Octane Exo Spinal): Sale of Octane Exo Spinal intervertebral implants made with HyperPEEK biocomposite. Currently seeking commercialization partners for global sales and distribution.
4. Medical Instrumentation and Components: Through Octane Clinical Systems, designs and manufactures medical instrumentation and disposable components for clinical applications. Currently produces radioisotope infusion lines for Jubilant's RUBY-FILL PET system under a multi-year agreement.
5. Cocoon Platform Manufacturing Systems: Manufacturing and commercialization of Cocoon automated cell therapy production systems. Lonza leads commercialization with Octane maintaining orthopedic applications through Octane Orthobiologics. The platform returns to full Octane ownership following 2026 acquisition of Lonza's Personalized Medicine business.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Octane is a medical technology company that develops advanced bioreactors, bioprocesses, and biomaterials for regenerative medicine. Its core Cocoon Platform is a first-of-its-kind automated production system for personalized, patient-scale cell therapies, integrating upstream and downstream processing in a closed, single-use disposable cassette. Octane also produces proprietary living tissue implants for cartilage repair (Novocart 3D and Novocart Inject), advanced biocomposite spinal implants (HyperPEEK, Octane Exo Spinal), and medical instrumentation for nuclear imaging, while operating a CDMO service for ATMP developers.

Product overview

Octane is a regenerative medicine technology company offering a platform-plus-modules architecture centered on the Cocoon automated cell therapy production system. The core Cocoon platform enables automated manufacturing of personalized cell therapies in a closed bioreactor system. This platform supports multiple product lines: Novocart 3D and Novocart Inject (cartilage repair implants acquired from B. Braun's orthobiologics business), Octane HyperPEEK biocomposite materials and Octane Exo Spinal implants (for bone regeneration and spinal reconstruction), and RUBY-FILL infusion lines (for PET medical imaging). The company also operates Octane CDMO, a contract development and manufacturing organization service leveraging the same Cocoon technology to serve third-party ATMP developers. All offerings are tied together through Octane's expertise in bioprocesses, biomaterials, and bioreactors for regenerative medicine.

Differentiator

Problem solved

Functional benefit

Brands

• Cocoon: Automated cell and tissue therapy production system (bioreactor) for personalized patient-scale cell therapies with applications in immunotherapy, regenerative medicine, and orthopedic treatments.
• Novocart
• HyperPEEK
• Skelite
• AUTOGRAFTA
• Exo Spinal

Products and services

• Cocoon Platform

Quantifiable outcome

• Over 30,000 cell therapy products manufactured for cartilage defects
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and major.

• BioOra LimitedcoreStrategic or Co-development Partner · 7 April 2026Collaboration for co-development and deployment of advanced cell therapies using Cocoon automated cell therapy manufacturing platform. Builds on existing CAR-T therapy manufacturing partnership in New Zealand. BioOra is constructing manufacturing facility in Christchurch designed to operate multiple Cocoon systems. Collaboration supports expansion across Australia, North America and international markets.
• Lonza GroupcoreStrategic or Co-development Partner · 3 March 2026Octane is acquiring Lonza's Personalized Medicine business including controlling stake in the Cocoon Platform (originally developed by Octane, acquired by Lonza in 2018). Transaction expected to close by end of Q1 2026, returning full ownership of Cocoon to Octane. Lonza previously acquired controlling stake in Octane Biotech in 2018 to accelerate clinical adoption of Cocoon technology. Partnership reflects Lonza's decision to focus on core CDMO operations.
• B. Braun (Aesculap AG)majorStrategic or Co-development Partner · 5 June 2024Octane acquired B. Braun's global orthobiologics business including TETEC AG in Germany and Aesculap Biologics LLC in the United States. Acquisition establishes Octane as international leader in regenerative medicine and brings full ownership of NOVOCART autologous chondrocyte implantation technology. Previously partnered with B. Braun for over 10 years to scale up production of living-tissue orthopedic implants.
• Jubilant Life SciencescoreStrategic or Co-development Partner · 1 October 2014Partnership for process engineering, process automation and manufacturing of radioisotope infusion lines for RUBY-FILL PET imaging system. Octane engineered comprehensive process for producing infusion lines that deliver rubidium Rb 82 chloride for PET imaging. Octane Clinical Systems produces all infusion systems for RUBY-FILL enabling early detection of coronary artery disease globally.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Miltenyi Biotec: Provides automated cell processing instruments and GMP cell manufacturing platforms (e.g., Prodigy) for cell and gene therapy developers. Directly comparable to Octane's Cocoon as a closed, automated, patient-scale cell therapy manufacturing platform.
• Organogenesis Holdings: Commercial-stage regenerative medicine company selling living tissue implants (Apligraf, Dermagraft) for wound care and surgical applications. Comparable to Octane as a commercial regenerative medicine business built around proprietary living-tissue and biomaterial products.
• Lonza Group: Global CDMO leader that historically held controlling stake in Octane Biotech and commercialized Cocoon for non-orthopedic cell therapy applications. Direct overlap in automated cell therapy manufacturing and ATMP CDMO services; Lonza is now divesting its Personalized Medicine business back to Octane.
• Vericel Corporation: Commercial-stage autologous cell therapy company marketing MACI (matrix-applied chondrocyte implant) for cartilage repair in the US. Closest direct competitor to Octane's Novocart franchise in autologous chondrocyte implantation for cartilage defects.

Others

• B. Braun (Aesculap): Former parent of Octane's now-acquired orthobiologics business (TETEC AG, Aesculap Biologics). Historical long-term commercialization partner and relevant comparable for orthopedic implant distribution and orthobiologics portfolio strategy.
• Jubilant Pharmova: Strategic partner that contracts Octane Clinical Systems to manufacture RUBY-FILL radioisotope infusion lines for PET imaging. Comparable as a nuclear medicine/PET imaging player and a counterparty whose volumes drive one of Octane's revenue streams.

Broad incumbents

• Catalent: Large diversified CDMO with growing cell and gene therapy manufacturing services including autologous cell therapy capabilities. Competes with Octane CDMO for ATMP developer contracts across cell therapy, gene therapy and biologics.
• Thermo Fisher Scientific (CDMO): Operates one of the world's largest CDMO networks through Patheon and viral vector/cell therapy services. Competes with Octane CDMO in advanced therapy manufacturing and bioprocessing instrumentation.
• Sartorius AG: Global supplier of bioprocessing equipment, single-use solutions and cell line development used in cell and gene therapy manufacturing. Overlaps with Octane in the upstream bioprocess tooling ecosystem that surrounds Cocoon and other ATMP platforms.
• Cytiva (Danaher): Bioprocessing equipment, single-use technologies and cell therapy workflow solutions provider. Competes with Octane CDMO/biotech offering on the bioprocess hardware layer that cell therapy developers purchase.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Octane